Skip to content
DataLookout
Menu

Lumiteg-INCT07891338

Exploratory Study of the Efficacy of HAL-PDT in CIN 3

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Pathological Regression Rate at 6 Months
Timeframe: 180 ±14 days after the first HAL-PDT treatment

Secondary (10)

Colposcopic Lesion Changes at 3 Months
Pathological Regression Rate at 12 Months
HPV Clearance Rate at 3 Months
HPV Clearance Rate at 6 Months
HPV Clearance Rate at 12 Months
Show 5 moreShow less
Treatment-Related Adverse Events
Correlation Between Baseline HPV Integration Status and 6-Month Pathological Response Rate
Correlation Between Baseline HPV Integration Status and HPV Clearance Rate
Cervical Exfoliated-Cell Gene Methylation Status
Cervical Exfoliated-Cell p16/Ki-67 Dual-Stain Status

Arms and interventions

HAL-PDTExperimental

Participants will receive hexaminolevulinate-mediated cervical photodynamic therapy using a 5% hexaminolevulinate ointment and a light fluence of 125 J/cm². Treatment will be administered once every 2 weeks for a total of 6 treatments

Combination products: Hexaminolevulinate (HAL)

Sites

1 site in 1 country

  • Tongji Hospital, Huazhong University of Science and TechnologyWuhan, Hubei, China